Non-small cell lung cancer (NSCLC) is the main reason of cancer linked mortality and around 80% of cases diagnosed in advanced stage. Therefore current study designed to evaluate the deregulation of miRNA-194 and miRNA-192 in different body fluid of Non small cell lung cancer participants. Present study recruited newly diagnosed histopathologically confirmed. It was observed that the 40% NSCLC participants showed elevated miR-194 expression and 60% NSCLC participants showed reduced miR-194 expression in serum sample while in Bronchial wash, only 20% NSCLC participants showed elevated miR-194 expression while 80% showed reduced miR-194 expression (p = 0.003). It was found that the 54% NSCLC participants showed elevated miR-192 expression and 55% NSCLC participants showed reduced miR-192 expression in serum sample while In Bronchial wash sample, only 25% NSCLC participants showed high miR-192 expression while 75% showed low miR-192 expression (P = 0.0004). Expression of miR-194 was significantly associated with TNM stages (p < 0.0001, p < 0.0001), distant organ metastases (p < 0.0001, p < 0.0001), pathological grade (p = 0.0009, p = 0.0005) among serum sample and bronchial wash sample. Same observation was found with expression of miR-192 and it was significantly associated with TNM stages (p < 0.0001, p < 0.0001), distant organ metastases (p < 0.0001, p < 0.0001), pathological grade (p = 0.006, p = 0.001) among serum sample and bronchial wash sample. It was observed that the NSCLC participants who had high serum based miR-194 expression showed 22 months of overall median survival while low expression of serum based miR-194 expression showed 18 months of overall median survival. Present study suggests that decreased expression of miR-194 and miR-192 was significantly associated with different clinical features of NSCLC cases. However, significantly higher number of NSCLC cases showed low expression of miR-194 and miR-192 in bronchial lavage sample. Decreased poor overall survival was found to be associated with bronchial wash sample with respect to low miR-194 and miR-192 expression while NSCLC participants showed better overall survival with high miR-194 and miR-192 expression. This suggested decreased expression of miR-192 and miR-194 expression could be the potential prognostic marker among NSCLC participants.

非小细胞肺癌（NSCLC）是与癌症相关的死亡率的主要原因，约80％的晚期病例被诊断出来。因此，当前的研究旨在评估非小细胞肺癌参与者不同体液中miRNA-194和miRNA-192的失调。本研究募集的新诊断经组织病理学证实。观察到40％的NSCLC参与者的血清样品中miR-194表达升高，而60％的NSCLC参与者的血清样品中miR-194表达降低，而在支气管冲洗液中，只有20％的NSCLC参与者的miR-194表达升高，而80％的患者的miR-194表达降低。 miR-194表达（p = 0.003）。发现在血清样本中有54％的NSCLC参与者显示了较高的miR-192表达，而55％的NSCLC参与者显示了降低的miR-192表达，而在支气管清洗样本中，只有25％的NSCLC参与者显示高miR-192表达，而75％则显示低miR-192表达（P = 0.0004）。miR-194的表达与TNM分期（p <0.0001，p <0.0001），远处器官转移（p <0.0001，p <0.0001），病理学分级（p = 0.0009，p = 0.0005）显着相关。洗涤样品。在miR-192的表达中发现了相同的观察结果，并且与TNM分期（p <0.0001，p <0.0001），远处器官转移（p <0.0001，p <0.0001），病理分级（p = 0.006，p =血清样品和支气管清洗样品中的0.001）。观察到具有高的基于血清的miR-194表达的NSCLC参与者显示出22个月的总体中位生存期，而低的基于血清的miR-194的表达表明18个月的总体中位生存期。目前的研究表明，miR-194和miR-192的表达下降与NSCLC病例的不同临床特征显着相关。但是，在支气管灌洗液样本中，明显多于NSCLC的病例显示出miR-194和miR-192的低表达。对于低miR-194和miR-192表达，发现不良的总生存率降低与支气管洗液样本有关，而NSCLC参与者在高miR-194和miR-192表达情况下表现出更好的总生存率。目前的研究表明，miR-194和miR-192的表达下降与NSCLC病例的不同临床特征显着相关。然而，明显更多的NSCLC病例在支气管灌洗液样本中显示出miR-194和miR-192的低表达。对于低miR-194和miR-192表达，发现不良的总生存率降低与支气管洗液样本有关，而NSCLC参与者在高miR-194和miR-192表达情况下表现出更好的总生存率。目前的研究表明，miR-194和miR-192的表达下降与NSCLC病例的不同临床特征显着相关。然而，明显更多的NSCLC病例在支气管灌洗液样本中显示出miR-194和miR-192的低表达。对于低miR-194和miR-192表达，发现不良的总生存率降低与支气管洗液样本有关，而NSCLC参与者在高miR-194和miR-192表达情况下表现出更好的总生存率。 这表明miR-192和miR-194表达的降低可能是NSCLC参与者中潜在的预后标志物。